ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
2,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2,4,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4,1,Vulval disorder,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
4,2,Vulvovaginal discomfort,Vulvovaginal signs and symptoms,Vulvovaginal disorders (excl infections and inflammations),Repro,N
5,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
5,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
5,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
6,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
6,2,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
7,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
7,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
8,1,Laryngeal oedema,"Laryngeal spasm, oedema and obstruction",Upper respiratory tract disorders (excl infections),Resp,N
9,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
9,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
9,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
10,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
10,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
11,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
11,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
12,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
12,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
12,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
13,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
13,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
14,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
15,1,Headache,Headaches NEC,Headaches,Nerv,N
16,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
16,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
16,3,Headache,Headaches NEC,Headaches,Nerv,N
17,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
17,2,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
18,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
19,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
20,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
21,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
22,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
22,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
23,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
23,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
23,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
23,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
24,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
24,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
25,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
26,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
26,2,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
27,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
28,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
29,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
29,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
30,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
30,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
30,3,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
30,4,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
30,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
30,6,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
31,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
31,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
31,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
32,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
33,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
34,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
34,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
35,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
36,1,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
36,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
37,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
38,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
39,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
40,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
40,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
41,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
42,1,Application site oedema,Application site reactions,Administration site reactions,Genrl,N
42,2,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
43,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
44,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
45,1,Balanoposthitis,Penile and scrotal infections and inflammations,Male reproductive tract infections and inflammations,Repro,N
46,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
47,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
48,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
49,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
49,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
50,1,Apnoeic attack,Breathing abnormalities,Respiratory disorders NEC,Resp,N
51,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
52,1,Bladder obstruction,Bladder disorders NEC,Bladder and bladder neck disorders (excl calculi),Renal,N
52,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
52,3,Vulval oedema,Vulvovaginal signs and symptoms,Vulvovaginal disorders (excl infections and inflammations),Repro,N
53,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
53,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
54,1,Erythema nodosum,Panniculitides,Skin and subcutaneous tissue disorders NEC,Skin,N
54,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
55,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
56,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
56,2,Cyanosis,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
57,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
58,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
59,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
59,2,Thrombophlebitis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
60,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
60,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
61,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
62,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
63,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
64,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
65,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
66,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
67,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
68,1,Oesophagitis,Oesophagitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
69,1,Device failure,Device issues NEC,Device issues,Prod,N
70,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
71,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
72,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
73,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
74,1,Pemphigoid,Bullous conditions,Epidermal and dermal conditions,Skin,N
75,1,Pigmentation disorder,Pigmentation changes NEC,Pigmentation disorders,Skin,N
75,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
76,1,Phlebitis,Phlebitis NEC,Vascular infections and inflammations,Vasc,N
77,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
78,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
79,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
80,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
81,1,Lip oedema,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
82,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
82,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
83,1,Anaphylactoid reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
84,1,Ventricular tachycardia,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
85,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
85,2,Vasculitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
86,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
86,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
87,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
88,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
89,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
90,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
91,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
92,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
93,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
93,2,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
94,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
94,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
95,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
95,2,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,Y
95,3,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
95,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
96,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
96,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
96,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
97,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
97,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
98,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
99,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
100,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
100,2,Prothrombin level increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
101,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
102,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
103,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
104,1,Prothrombin level increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
104,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
105,1,Rash morbilliform,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
106,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
107,1,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
108,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
109,1,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
110,1,Lichenoid keratosis,Hyperkeratoses,Cornification and dystrophic skin disorders,Skin,N
110,2,Vulval disorder,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
111,1,Lichenoid keratosis,Hyperkeratoses,Cornification and dystrophic skin disorders,Skin,N
111,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
111,3,Vulval disorder,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
112,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
113,1,Atrioventricular block,Cardiac conduction disorders,Cardiac arrhythmias,Card,Y
113,2,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
113,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
114,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
114,2,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
115,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
116,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
117,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
117,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
118,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
119,1,Breath holding,Abnormal behaviour NEC,Psychiatric and behavioural symptoms NEC,Psych,N
120,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
120,2,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
120,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
121,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
122,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
122,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
123,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
124,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
125,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
126,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
127,1,Ventricular fibrillation,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
128,1,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
128,2,Pruritus genital,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
128,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
129,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
130,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
131,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
132,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
132,2,Behaviour disorder,Abnormal behaviour NEC,Psychiatric and behavioural symptoms NEC,Psych,N
133,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
133,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
134,1,Anaphylactoid reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
135,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
136,1,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
136,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
136,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
137,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
137,2,Conjunctivitis,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
138,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
139,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
140,1,Inhibitory drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
140,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
141,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
142,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
142,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
143,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
143,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
143,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
143,4,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
144,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
145,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
145,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
145,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
146,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
146,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
146,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
147,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
148,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
148,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
148,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
149,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
150,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
151,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
152,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
152,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
153,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
153,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
154,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
154,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
155,1,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
156,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
156,2,Vaginal infection,Female reproductive tract infections,Infections - pathogen unspecified,Infec,N
157,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
157,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
158,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
159,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
159,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
159,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
160,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
161,1,Eye infection bacterial,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
162,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
162,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
162,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
162,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
162,5,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
162,6,Sinus tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
163,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
163,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
164,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
165,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
165,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
166,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
166,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
167,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
167,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
167,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
168,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
168,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
169,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
169,2,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
170,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
171,1,Hyperaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
172,1,Vaginal infection,Female reproductive tract infections,Infections - pathogen unspecified,Infec,N
173,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
174,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
174,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
174,3,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
175,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
175,2,Perineal pain,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
175,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
176,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
176,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
177,1,Application site oedema,Application site reactions,Administration site reactions,Genrl,N
178,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
178,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
178,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
178,4,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
179,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
179,2,Periodontitis,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
179,3,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
180,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
181,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
182,1,Headache,Headaches NEC,Headaches,Nerv,N
182,2,Pharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
183,1,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
183,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
184,1,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
184,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
185,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
186,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
187,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
188,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
189,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
189,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
190,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
191,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
192,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
192,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
193,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
193,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
194,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
194,2,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
195,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
195,2,Prothrombin level increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
196,1,Skin depigmentation,Hypopigmentation disorders,Pigmentation disorders,Skin,N
197,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
198,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
198,2,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
199,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
200,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
200,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
201,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
202,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
203,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
204,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
204,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
205,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
206,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
207,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
208,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
208,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
208,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
209,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
209,2,Headache,Headaches NEC,Headaches,Nerv,N
210,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
211,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
211,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
212,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
213,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
214,1,Urinary retention,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
214,2,Vaginal discharge,Vulvovaginal signs and symptoms,Vulvovaginal disorders (excl infections and inflammations),Repro,N
214,3,Vulval disorder,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
215,1,Laryngeal oedema,"Laryngeal spasm, oedema and obstruction",Upper respiratory tract disorders (excl infections),Resp,N
215,2,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
215,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
216,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
216,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
217,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
217,2,Pruritus genital,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
218,1,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
218,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
219,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
219,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
219,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
219,4,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
219,5,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
219,6,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
220,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
221,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
222,1,Hepatitis acute,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
222,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
223,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
223,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
224,1,Vaginal infection,Female reproductive tract infections,Infections - pathogen unspecified,Infec,N
225,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
226,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
226,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
227,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
227,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
228,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
229,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
230,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
230,2,Vulval disorder,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
231,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
231,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
232,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
233,1,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
234,1,Penis disorder,Penile disorders NEC (excl erection and ejaculation),Penile and scrotal disorders (excl infections and inflammations),Repro,N
235,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
236,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
236,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
236,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
237,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
238,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
238,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
238,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
239,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
239,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
240,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
241,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
241,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
241,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
241,4,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
242,1,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
243,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
244,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
244,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
245,1,Migraine,Migraine headaches,Headaches,Nerv,N
246,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
247,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
247,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
247,3,Nasal congestion,Nasal congestion and inflammations,Upper respiratory tract disorders (excl infections),Resp,N
247,4,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
248,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
248,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
249,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
250,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
250,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
250,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
251,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
251,2,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
251,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
251,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
252,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
252,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
253,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
253,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
254,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
254,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
255,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
255,2,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
256,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
257,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
257,2,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
258,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
258,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
259,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
260,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
260,2,Ejaculation disorder,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
260,3,Emotional disorder,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
260,4,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
260,5,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
260,6,Male reproductive tract disorder,Reproductive tract disorders NEC (excl neoplasms),Reproductive tract disorders NEC,Repro,N
260,7,Sexual dysfunction,Sexual function and fertility disorders NEC,Sexual function and fertility disorders,Repro,N
260,8,Testicular pain,Testicular and epididymal disorders NEC,Testicular and epididymal disorders,Repro,N
261,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
262,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
263,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
263,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
264,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
264,2,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
265,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
265,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
266,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
266,2,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
266,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
267,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
267,2,Petechiae,Purpura and related conditions,Skin vascular abnormalities,Skin,N
268,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
268,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
269,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
270,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
271,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
272,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
272,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
273,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
273,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
273,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
274,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
275,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
275,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
275,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
276,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
276,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
276,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
276,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
277,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
277,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
277,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
278,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
279,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
279,2,Liver tenderness,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
279,3,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
280,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
280,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
280,3,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
281,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
281,2,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
282,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
282,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
283,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
283,2,Tongue movement disturbance,Tongue signs and symptoms,Tongue conditions,Gastr,N
284,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
284,2,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
284,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
284,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
284,5,Dry throat,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
284,6,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
284,7,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
284,8,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
284,9,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
284,10,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
284,11,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
284,12,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
284,13,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
284,14,Tongue coated,Tongue signs and symptoms,Tongue conditions,Gastr,N
285,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
285,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
286,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
286,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
286,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
286,4,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
286,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
286,6,Joint dislocation,Fractures and dislocations NEC,Bone and joint injuries,Inj&P,N
286,7,Oesophageal ulcer,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
286,8,Upper limb fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
287,1,Anger,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
287,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
287,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
287,4,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
288,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
288,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
289,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
290,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
290,2,Drug dependence,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
290,3,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
290,4,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
291,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
291,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
292,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
292,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
292,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
293,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
294,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
294,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
295,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
296,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
296,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
297,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
297,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
298,1,Blood calcium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
298,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
298,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
298,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
298,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
299,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
299,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
299,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
300,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
300,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
301,1,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
301,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
301,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
301,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
302,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
303,1,Cutaneous vasculitis,Skin vasculitides,Skin vascular abnormalities,Skin,N
304,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
304,2,Food interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
304,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
305,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
305,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
306,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
306,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
306,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
307,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
308,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
308,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
309,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
309,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
310,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
310,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
311,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
312,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
312,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
313,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
314,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
314,2,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
315,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
315,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
315,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
316,1,Adrenal insufficiency,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
316,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
317,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
317,2,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
318,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
319,1,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
320,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
321,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
321,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
322,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
323,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
323,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
324,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
324,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
324,3,Inflammation,Inflammations,General system disorders NEC,Genrl,N
324,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
324,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
324,6,Tinea pedis,Tinea infections,Fungal infectious disorders,Infec,N
325,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
325,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
325,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
326,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
327,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
328,1,Choking,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
328,2,Cyanosis,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
328,3,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
328,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
328,5,Respiratory arrest,Breathing abnormalities,Respiratory disorders NEC,Resp,N
328,6,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
329,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
329,2,Mouth swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
329,3,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
329,4,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
330,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
330,2,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
330,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
330,4,Respiratory arrest,Breathing abnormalities,Respiratory disorders NEC,Resp,N
331,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
332,1,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
332,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
333,1,Genital burning sensation,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
333,2,Nasal discomfort,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
333,3,Oral discomfort,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
333,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
333,5,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
334,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
334,2,International normalised ratio fluctuation,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
335,1,Anaphylactic shock,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
336,1,Blood blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
336,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
336,3,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
336,4,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
336,5,Prothrombin time ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
337,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
337,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
337,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
337,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
338,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
338,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
338,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
339,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
339,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
339,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
340,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
340,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
341,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
341,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
341,3,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
341,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
342,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
342,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
343,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
343,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
343,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
344,1,Face injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
344,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
344,3,Product administered at inappropriate site,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
344,4,Scar,Skin injuries NEC,Injuries NEC,Inj&P,N
344,5,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
345,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
345,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
345,3,Prothrombin time ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
346,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
347,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
347,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
348,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
348,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
349,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
349,2,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
349,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
349,4,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
349,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
350,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
350,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
351,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
351,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
351,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
351,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
351,5,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
351,6,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
352,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
352,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
353,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
353,2,Encephalitis fungal,Fungal infections NEC,Fungal infectious disorders,Infec,Y
353,3,Fungal sepsis,Fungal infections NEC,Fungal infectious disorders,Infec,N
354,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
355,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
355,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
355,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
355,4,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
355,5,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
355,6,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
355,7,Skin haemorrhage,Skin haemorrhages,Skin vascular abnormalities,Skin,N
355,8,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
355,9,Thermal burn,Thermal burns,Injuries by physical agents,Inj&P,N
356,1,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
357,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
358,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
358,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
359,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
360,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
360,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
361,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
362,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
363,1,Abdominal pain lower,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
363,2,Pelvic pain,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
363,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
364,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
364,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
365,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
365,2,Blood test abnormal,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
365,3,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
365,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
365,5,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
365,6,Hepatic steatosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
365,7,Hepatomegaly,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
365,8,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
365,9,Sensory disturbance,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
366,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
366,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
367,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
367,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
368,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
368,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
368,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,Y
368,4,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
369,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
369,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
369,3,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
369,4,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
369,5,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
369,6,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
370,1,Thermal burn,Thermal burns,Injuries by physical agents,Inj&P,N
371,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
371,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
371,3,Tongue ulceration,Tongue disorders,Tongue conditions,Gastr,N
372,1,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
372,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
373,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
373,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
373,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
374,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
374,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
374,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
375,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
375,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
375,3,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
376,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
376,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
376,3,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
377,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
377,2,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
378,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
378,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
378,3,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
379,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
380,1,International normalised ratio abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
381,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
381,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
382,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
382,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
383,1,Breast discharge,Breast signs and symptoms,Breast disorders,Repro,N
383,2,Nipple pain,Breast signs and symptoms,Breast disorders,Repro,N
384,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
384,2,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
384,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
384,4,Tenderness,Pain and discomfort NEC,General system disorders NEC,Genrl,N
385,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
386,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
386,2,Immune system disorder,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
386,3,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
387,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
388,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
388,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
389,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
389,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
389,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
390,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
390,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
390,3,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
391,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
391,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
391,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
392,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
393,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
393,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
394,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
395,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
396,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
396,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
397,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
397,2,Skin abrasion,Skin injuries NEC,Injuries NEC,Inj&P,N
398,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
398,2,Tinea pedis,Tinea infections,Fungal infectious disorders,Infec,N
399,1,Application site rash,Application site reactions,Administration site reactions,Genrl,N
399,2,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
400,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
400,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
400,3,Duodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
400,4,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
400,5,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
400,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
400,7,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
400,8,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
401,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
401,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
401,3,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
401,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
401,5,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
401,6,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
401,7,Feeding disorder,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
401,8,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
401,9,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
401,10,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
401,11,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
401,12,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
401,13,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
401,14,Therapeutic product effect increased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
402,1,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
402,2,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
402,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
403,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
403,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
404,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
404,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
404,3,Prothrombin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
405,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
405,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
405,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
406,1,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
406,2,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
406,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
406,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
406,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
406,6,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
407,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
407,2,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
407,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
407,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
408,1,Lip blister,Oral soft tissue disorders NEC,Oral soft tissue conditions,Gastr,N
408,2,Oral discomfort,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
409,1,Application site inflammation,Application site reactions,Administration site reactions,Genrl,N
409,2,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
409,3,Application site swelling,Application site reactions,Administration site reactions,Genrl,N
409,4,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
409,5,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
409,6,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
409,7,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
409,8,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
409,9,Limb mass,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
409,10,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
410,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
410,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
410,3,Foreign body,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
410,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
410,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
411,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
411,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
412,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
412,2,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
412,3,Application site rash,Application site reactions,Administration site reactions,Genrl,N
413,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
413,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
413,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
413,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
413,5,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
414,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
414,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
414,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
415,1,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
415,2,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
416,1,Retching,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
417,1,Dark circles under eyes,Ocular disorders NEC,Eye disorders NEC,Eye,N
417,2,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
417,3,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
417,4,Lip blister,Oral soft tissue disorders NEC,Oral soft tissue conditions,Gastr,N
417,5,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
417,6,Ocular hyperaemia,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
417,7,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
417,8,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
417,9,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
417,10,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
417,11,Skin fissures,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
417,12,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
418,1,Vulvovaginal burning sensation,Vulvovaginal signs and symptoms,Vulvovaginal disorders (excl infections and inflammations),Repro,N
419,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
419,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
419,3,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
419,4,Hemiplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
419,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
420,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
421,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
421,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
421,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
421,4,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
422,1,Vulvovaginal burning sensation,Vulvovaginal signs and symptoms,Vulvovaginal disorders (excl infections and inflammations),Repro,N
423,1,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
423,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
423,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
423,4,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
423,5,Product packaging issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
424,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
424,2,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
424,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
424,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
424,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
425,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
425,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
425,3,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
426,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
427,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
427,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
428,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
428,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
429,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
429,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
430,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
430,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
430,3,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
430,4,Haemorrhage urinary tract,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
430,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
431,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
431,2,Application site pain,Application site reactions,Administration site reactions,Genrl,N
431,3,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
432,1,Application site erosion,Application site reactions,Administration site reactions,Genrl,N
432,2,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
432,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
433,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
434,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
434,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
434,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
434,4,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
435,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
435,2,Polymyalgia rheumatica,Connective tissue disorders NEC,Connective tissue disorders (excl congenital),Musc,N
436,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
437,1,Phlebitis,Phlebitis NEC,Vascular infections and inflammations,Vasc,N
437,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
438,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
439,1,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
440,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
440,2,Hypoaesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
440,3,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
440,4,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
440,5,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
441,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
441,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
442,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
442,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
442,3,Swelling of eyelid,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
443,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
443,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
443,3,Tongue ulceration,Tongue disorders,Tongue conditions,Gastr,N
444,1,Vulvovaginal pruritus,Vulvovaginal signs and symptoms,Vulvovaginal disorders (excl infections and inflammations),Repro,N
445,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
446,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
446,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
446,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
446,4,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
447,1,Hyperkeratosis,Hyperkeratoses,Cornification and dystrophic skin disorders,Skin,N
448,1,Tooth discolouration,Dental surface disorders,Dental and gingival conditions,Gastr,N
449,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
449,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
450,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
450,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
450,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
451,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
451,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
451,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
452,1,Scab,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
452,2,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
452,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
453,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
453,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
453,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
453,4,Skin mass,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
454,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
454,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
455,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
456,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
456,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
457,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
457,2,Pathogen resistance,Infections NEC,Infections - pathogen unspecified,Infec,N
457,3,Spermatozoa morphology abnormal,Fertility analyses and other reproductive function procedures,Reproductive organ and breast investigations (excl hormone analyses),Inv,N
458,1,Application site burn,Application site reactions,Administration site reactions,Genrl,N
458,2,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
459,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
459,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
460,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
460,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
461,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
461,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
462,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
462,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
462,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
463,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
463,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
463,3,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
464,1,Chest wall haematoma,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
464,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
464,3,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
464,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
465,1,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
466,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
466,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
467,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
467,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
467,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
467,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
468,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
468,2,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
468,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
468,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
469,1,Skin fissures,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
470,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
470,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
470,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
471,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
472,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
473,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
473,2,Urinary bladder haemorrhage,Bladder disorders NEC,Bladder and bladder neck disorders (excl calculi),Renal,N
474,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
474,2,Vasculitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
475,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
475,2,Hair colour changes,Pilar disorders NEC,Skin appendage conditions,Skin,N
476,1,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
477,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
477,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
478,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
478,2,Body temperature fluctuation,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
478,3,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
478,4,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
478,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
478,6,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
478,7,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
478,8,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
479,1,Anticoagulation drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
479,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
479,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
480,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
480,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
481,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
482,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
483,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
483,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
483,3,Throat irritation,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
483,4,Tongue disorder,Tongue disorders,Tongue conditions,Gastr,N
483,5,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
484,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
484,2,Circumstance or information capable of leading to medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
484,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
484,4,Drug withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
484,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
484,6,Malabsorption,Malabsorption syndromes,Malabsorption conditions,Gastr,N
484,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
484,8,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
484,9,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
484,10,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
484,11,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
485,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
485,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
485,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
486,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
486,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
487,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
487,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
488,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
488,2,Renal aplasia,Renal disorders congenital,Renal and urinary tract disorders congenital,Cong,N
489,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
490,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
490,2,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
490,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
490,4,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
491,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
491,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
492,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
492,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
493,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
494,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
494,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
495,1,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
496,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
496,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
497,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
497,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
497,3,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
497,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
498,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
498,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
499,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
499,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
500,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
500,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
500,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
500,4,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
500,5,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
500,6,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
500,7,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
501,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
501,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
501,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
502,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
503,1,Balanoposthitis,Penile and scrotal infections and inflammations,Male reproductive tract infections and inflammations,Repro,N
504,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
504,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
505,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
505,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
506,1,Gastroenteritis viral,Viral infections NEC,Viral infectious disorders,Infec,N
506,2,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
506,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
507,1,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
507,2,Skin depigmentation,Hypopigmentation disorders,Pigmentation disorders,Skin,N
508,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
508,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
508,3,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
509,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
509,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
510,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
511,1,Application site inflammation,Application site reactions,Administration site reactions,Genrl,N
512,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
512,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
512,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
513,1,Gingival swelling,"Gingival disorders, signs and symptoms NEC",Dental and gingival conditions,Gastr,N
513,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
513,3,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
513,4,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
514,1,Rash vesicular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
515,1,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
516,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
516,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
517,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
518,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
518,2,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
518,3,Application site pain,Application site reactions,Administration site reactions,Genrl,N
518,4,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
518,5,Application site swelling,Application site reactions,Administration site reactions,Genrl,N
518,6,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
519,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
519,2,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
519,3,Tongue blistering,Tongue signs and symptoms,Tongue conditions,Gastr,N
520,1,Application site swelling,Application site reactions,Administration site reactions,Genrl,N
521,1,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
522,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
523,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
523,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
523,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
524,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
524,2,Reaction to excipient,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
524,3,Salivary hypersecretion,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
525,1,Acne,Acnes,Skin appendage conditions,Skin,N
525,2,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
525,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
526,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
527,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
528,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
528,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
529,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
529,2,Application site pain,Application site reactions,Administration site reactions,Genrl,N
530,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
530,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
530,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
531,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
531,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
532,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
532,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
533,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
533,2,Inflammation,Inflammations,General system disorders NEC,Genrl,N
533,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
534,1,Brain injury,Structural brain disorders NEC,Structural brain disorders,Nerv,N
534,2,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
535,1,Eyelid ptosis,Eyelid movement disorders,Ocular neuromuscular disorders,Eye,N
535,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
535,3,Ocular myasthenia,Ocular nerve and muscle disorders,Ocular neuromuscular disorders,Eye,N
536,1,Oral mucosal blistering,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
536,2,Tongue discomfort,Tongue signs and symptoms,Tongue conditions,Gastr,N
537,1,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
538,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
538,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
539,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
539,2,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
540,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
540,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
540,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
540,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
540,5,Skin erosion,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
540,6,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
541,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
541,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
542,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
542,2,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
543,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
543,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
544,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
544,2,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
544,3,Vulvovaginal burning sensation,Vulvovaginal signs and symptoms,Vulvovaginal disorders (excl infections and inflammations),Repro,N
545,1,Application site dryness,Application site reactions,Administration site reactions,Genrl,N
545,2,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
545,3,Application site exfoliation,Application site reactions,Administration site reactions,Genrl,N
545,4,Application site pain,Application site reactions,Administration site reactions,Genrl,N
545,5,Application site pain,Application site reactions,Administration site reactions,Genrl,N
545,6,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
545,7,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
545,8,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
546,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
546,2,Dermatitis diaper,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
547,1,Acarodermatitis,Ectoparasitic infestations,Ectoparasitic disorders,Infec,N
547,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
548,1,Vomiting projectile,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
549,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
550,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
550,2,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
550,3,Oral mucosal erythema,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
551,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
551,2,Internal haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
552,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
552,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
553,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
553,2,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
553,3,Muscle discomfort,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
554,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
554,2,Application site inflammation,Application site reactions,Administration site reactions,Genrl,N
554,3,Application site pain,Application site reactions,Administration site reactions,Genrl,N
554,4,Application site pain,Application site reactions,Administration site reactions,Genrl,N
554,5,Application site paraesthesia,Application site reactions,Administration site reactions,Genrl,N
554,6,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
554,7,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
555,1,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
556,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
556,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
557,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
557,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
558,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
558,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
558,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
558,4,Skin fissures,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
559,1,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
559,2,Sunburn,Radiation injuries,Injuries by physical agents,Inj&P,N
560,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
560,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
561,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
561,2,Genital burning sensation,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
561,3,Genital erythema,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
561,4,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
561,5,Skin hypertrophy,Skin hyperplasias and hypertrophies,Cornification and dystrophic skin disorders,Skin,N
562,1,Throat irritation,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
563,1,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
563,2,Sensitive skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
563,3,Skin atrophy,Skin hypoplasias and atrophies,Cornification and dystrophic skin disorders,Skin,N
563,4,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
563,5,Skin texture abnormal,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
563,6,Urethral pain,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
563,7,Urinary tract injury,Renal and urinary tract injuries NEC,Injuries NEC,Inj&P,N
564,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
564,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
565,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
565,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
565,3,Impaired healing,Healing abnormal NEC,Tissue disorders NEC,Genrl,N
565,4,Skin atrophy,Skin hypoplasias and atrophies,Cornification and dystrophic skin disorders,Skin,N
566,1,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
567,1,Glossodynia,Tongue signs and symptoms,Tongue conditions,Gastr,N
567,2,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
568,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
568,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
569,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
569,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
569,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
569,4,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
569,5,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
569,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
569,7,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
570,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
571,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
571,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
571,3,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
572,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
572,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
573,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
573,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
573,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
574,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
575,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
575,2,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
575,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
575,4,Inflammation,Inflammations,General system disorders NEC,Genrl,N
575,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
575,6,Skin fissures,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
576,1,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
576,2,Impaired healing,Healing abnormal NEC,Tissue disorders NEC,Genrl,N
577,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
577,2,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
577,3,Tongue discolouration,Tongue signs and symptoms,Tongue conditions,Gastr,N
578,1,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
578,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
579,1,Application site rash,Application site reactions,Administration site reactions,Genrl,N
580,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
580,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
581,1,Application site hypoaesthesia,Application site reactions,Administration site reactions,Genrl,N
582,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
583,1,Choking,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
584,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
584,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
584,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
584,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
585,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
585,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
586,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
586,2,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
587,1,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
587,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
588,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
588,2,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
588,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
589,1,Application site burn,Application site reactions,Administration site reactions,Genrl,N
589,2,Application site pain,Application site reactions,Administration site reactions,Genrl,N
590,1,Palatal swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
590,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
591,1,Tongue discolouration,Tongue signs and symptoms,Tongue conditions,Gastr,N
592,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
592,2,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
593,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
594,1,Choking,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
595,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
595,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
596,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
596,2,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
596,3,Oral pustule,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
596,4,Tongue discolouration,Tongue signs and symptoms,Tongue conditions,Gastr,N
597,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
597,2,Product label issue,Product label issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
598,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
598,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
598,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
599,1,Oral discomfort,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
599,2,Oral mucosal blistering,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
599,3,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
599,4,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
600,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
600,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
600,3,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
601,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
601,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
601,3,Headache,Headaches NEC,Headaches,Nerv,N
601,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
601,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
602,1,Choking,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
603,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
603,2,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
603,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
604,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
604,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
605,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
606,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
606,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
606,3,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
606,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
606,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
606,6,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
606,7,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
607,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
607,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
607,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
607,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
608,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
608,2,Heart rate decreased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
608,3,Lip disorder,Oral soft tissue disorders NEC,Oral soft tissue conditions,Gastr,N
608,4,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
609,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
609,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
610,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
610,2,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
610,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
611,1,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
611,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
611,3,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
612,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
612,2,Internal haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
612,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
613,1,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
613,2,Throat irritation,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
614,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
614,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
615,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
615,2,Internal haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
615,3,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
615,4,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
616,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
616,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
617,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
617,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
617,3,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
618,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
618,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
618,3,Prothrombin time ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
619,1,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
619,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
620,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
620,2,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
621,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
621,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
622,1,Coeliac disease,Malabsorption syndromes,Malabsorption conditions,Gastr,N
623,1,Asthenopia,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
623,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
623,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
624,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
624,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
625,1,Papule,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
625,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
626,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
626,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
626,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
627,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
627,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
628,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
628,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
629,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
629,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
630,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
630,2,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
630,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
630,4,Discoloured vomit,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
630,5,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
630,6,Drug monitoring procedure not performed,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
630,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
631,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
632,1,Infected skin ulcer,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
632,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
632,3,Thermal burn,Thermal burns,Injuries by physical agents,Inj&P,N
633,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
633,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
634,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
634,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
635,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
635,2,Drug dependence,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
635,3,Dysstasia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
635,4,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
635,5,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
635,6,Inflammation,Inflammations,General system disorders NEC,Genrl,N
635,7,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
635,8,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
635,9,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
635,10,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
635,11,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
635,12,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
635,13,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
635,14,Steroid withdrawal syndrome,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
636,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
636,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
636,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
637,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
638,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
638,2,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
638,3,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
638,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
638,5,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
639,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
639,2,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
639,3,Skin swelling,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
640,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
641,1,Asthenopia,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
641,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
641,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
642,1,Anaphylactoid reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
643,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
644,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
645,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
646,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
647,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
648,1,Abnormal behaviour,Abnormal behaviour NEC,Psychiatric and behavioural symptoms NEC,Psych,N
648,2,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
648,3,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
648,4,Drug monitoring procedure not performed,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
648,5,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
648,6,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
648,7,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
649,1,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
650,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
650,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
650,3,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
651,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
651,2,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
651,3,Skin swelling,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
652,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
652,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
653,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
654,1,Application site rash,Application site reactions,Administration site reactions,Genrl,N
655,1,Allergic reaction to excipient,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
655,2,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
655,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
656,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
656,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
657,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
657,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
658,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
658,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
659,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
659,2,Application site inflammation,Application site reactions,Administration site reactions,Genrl,N
660,1,Mouth swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
660,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
661,1,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
662,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
662,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
662,3,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
662,4,Skin warm,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
663,1,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
664,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
664,2,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
665,1,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
665,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
666,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
667,1,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
667,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
668,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
668,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
668,3,Nail discolouration,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
668,4,Nail disorder,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
669,1,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
670,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
670,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
671,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
672,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
672,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
672,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
672,4,Muscle rigidity,Muscle tone abnormalities,Muscle disorders,Musc,N
672,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
672,6,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
672,7,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
672,8,Skin weeping,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
673,1,Oral mucosal eruption,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
674,1,Application site rash,Application site reactions,Administration site reactions,Genrl,N
675,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
675,2,Application site discolouration,Application site reactions,Administration site reactions,Genrl,N
675,3,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
675,4,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
675,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
676,1,Tunnel vision,Neurologic visual problems NEC,Neurological disorders of the eye,Nerv,N
677,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
677,2,Obstructive airways disorder,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
677,3,Pharyngeal haematoma,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
678,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
678,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
678,3,Obstructive airways disorder,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
678,4,Pharyngeal haematoma,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
679,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
680,1,Application site rash,Application site reactions,Administration site reactions,Genrl,N
681,1,Breast pain,Breast signs and symptoms,Breast disorders,Repro,N
681,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
681,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
681,4,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
682,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
682,2,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
682,3,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
682,4,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
682,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
682,6,Formication,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
682,7,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
682,8,Neuralgia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
682,9,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
682,10,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
682,11,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
682,12,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
682,13,Scab,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
682,14,Skin atrophy,Skin hypoplasias and atrophies,Cornification and dystrophic skin disorders,Skin,N
682,15,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
682,16,Skin hyperpigmentation,Hyperpigmentation disorders,Pigmentation disorders,Skin,N
682,17,Skin infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
682,18,Skin swelling,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
682,19,Skin tightness,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
682,20,Skin weeping,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
682,21,Skin wrinkling,Skin dystrophies,Cornification and dystrophic skin disorders,Skin,N
682,22,Steroid withdrawal syndrome,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
683,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
683,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
684,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
684,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
684,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
685,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
686,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
687,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
687,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
688,1,Chapped lips,Oral soft tissue disorders NEC,Oral soft tissue conditions,Gastr,N
688,2,Crohn's disease,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
688,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
688,4,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
688,5,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
688,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
688,7,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
688,8,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
688,9,Seborrhoeic dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
688,10,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
689,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
690,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
691,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
692,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
692,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
693,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
693,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
693,3,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
694,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
694,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
694,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
695,1,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
695,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
696,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
697,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
697,2,Pharyngeal haematoma,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
697,3,Upper airway obstruction,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
698,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
698,2,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
698,3,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
698,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
698,5,Obstructive airways disorder,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
698,6,Pharyngeal haematoma,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
699,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
699,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
699,3,Tongue pruritus,Tongue signs and symptoms,Tongue conditions,Gastr,N
699,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
700,1,Retching,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
701,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
701,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
701,3,Nasal congestion,Nasal congestion and inflammations,Upper respiratory tract disorders (excl infections),Resp,N
701,4,Oral mucosal blistering,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
701,5,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
702,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
703,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
703,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
703,3,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
703,4,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
703,5,Pharyngeal haematoma,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
704,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
705,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
706,1,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
707,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
708,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
708,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
709,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
710,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
710,2,Hypoaesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
710,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
711,1,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
711,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
712,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
713,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
714,1,Presyncope,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
714,2,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
715,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
716,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
717,1,Application site exfoliation,Application site reactions,Administration site reactions,Genrl,N
718,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
719,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
719,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
720,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
721,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
722,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
722,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
722,3,Penile pain,Penile disorders NEC (excl erection and ejaculation),Penile and scrotal disorders (excl infections and inflammations),Repro,N
722,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
722,5,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
722,6,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
723,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
723,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
723,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
723,4,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
723,5,Sensitive skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
723,6,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
723,7,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
723,8,Skin infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
723,9,Skin swelling,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
723,10,Skin weeping,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
724,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
725,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
726,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
727,1,Maternal exposure during breast feeding,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
728,1,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
729,1,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
729,2,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
730,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
730,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
731,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
732,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
732,2,Skin erosion,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
732,3,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
733,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
734,1,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
734,2,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
735,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
735,2,Acne,Acnes,Skin appendage conditions,Skin,N
735,3,Alopecia,Alopecias,Skin appendage conditions,Skin,N
735,4,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
735,5,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
735,6,CD4 lymphocytes decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
735,7,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
735,8,Dandruff,Scaly conditions,Epidermal and dermal conditions,Skin,N
735,9,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
735,10,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
735,11,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
735,12,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
735,13,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
735,14,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
735,15,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
735,16,Ejaculation disorder,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
735,17,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
735,18,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
735,19,Eye movement disorder,Ocular nerve and muscle disorders,Ocular neuromuscular disorders,Eye,N
735,20,Eyelid margin crusting,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
735,21,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
735,22,Headache,Headaches NEC,Headaches,Nerv,N
735,23,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
735,24,Increased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
735,25,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
735,26,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
735,27,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
735,28,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
735,29,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
735,30,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
735,31,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
735,32,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
735,33,Restlessness,Increased physical activity levels,Changes in physical activity,Psych,N
735,34,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
735,35,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
735,36,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
735,37,Skin fissures,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
735,38,Skin hypertrophy,Skin hyperplasias and hypertrophies,Cornification and dystrophic skin disorders,Skin,N
735,39,Skin infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
735,40,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
735,41,Toothache,Dental pain and sensation disorders,Dental and gingival conditions,Gastr,N
735,42,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
735,43,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
736,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
737,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
737,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
738,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
738,2,Acne,Acnes,Skin appendage conditions,Skin,N
738,3,Alopecia,Alopecias,Skin appendage conditions,Skin,N
738,4,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
738,5,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
738,6,CD4 lymphocytes decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
738,7,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
738,8,Dandruff,Scaly conditions,Epidermal and dermal conditions,Skin,N
738,9,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
738,10,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
738,11,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
738,12,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
738,13,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
738,14,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
738,15,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
738,16,Ejaculation disorder,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
738,17,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
738,18,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
738,19,Eye movement disorder,Ocular nerve and muscle disorders,Ocular neuromuscular disorders,Eye,N
738,20,Eyelid margin crusting,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
738,21,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
738,22,Headache,Headaches NEC,Headaches,Nerv,N
738,23,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
738,24,Increased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
738,25,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
738,26,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
738,27,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
738,28,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
738,29,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
738,30,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
738,31,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
738,32,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
738,33,Restlessness,Increased physical activity levels,Changes in physical activity,Psych,N
738,34,Rhabdomyolysis,Myopathies,Muscle disorders,Musc,N
738,35,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
738,36,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
738,37,Skin fissures,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
738,38,Skin hypertrophy,Skin hyperplasias and hypertrophies,Cornification and dystrophic skin disorders,Skin,N
738,39,Skin infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
738,40,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
738,41,Toothache,Dental pain and sensation disorders,Dental and gingival conditions,Gastr,N
738,42,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
738,43,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
739,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
739,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
740,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
741,1,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
742,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
742,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
742,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
743,1,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
744,1,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
744,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
744,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
744,4,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
744,5,Oral pruritus,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
744,6,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
745,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
745,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
746,1,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
746,2,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
747,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
747,2,Skin swelling,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
747,3,Tattoo associated skin reaction,Skin procedural complications,Procedural related injuries and complications NEC,Inj&P,N
748,1,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
748,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
749,1,Application site discolouration,Application site reactions,Administration site reactions,Genrl,N
749,2,Application site swelling,Application site reactions,Administration site reactions,Genrl,N
750,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
750,2,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
751,1,Sensitive skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
752,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
753,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
753,2,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
753,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
754,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
755,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
755,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
755,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
756,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
756,2,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
757,1,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
757,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
757,3,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
758,1,Application site burn,Application site reactions,Administration site reactions,Genrl,N
759,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
759,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
759,3,Skin weeping,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
759,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
760,1,Severe cutaneous adverse reaction,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
761,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
762,1,Choking,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
763,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
763,2,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
763,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
764,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
765,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
765,2,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
766,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
767,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
768,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
769,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
770,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
770,2,Skin fissures,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
771,1,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
772,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
772,2,Rash vesicular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
772,3,Skin erosion,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
772,4,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
772,5,Skin weeping,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
773,1,Burn oesophageal,Thermal burns,Injuries by physical agents,Inj&P,N
774,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
775,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
776,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
777,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
777,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
777,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
777,4,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
777,5,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
778,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
778,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
778,3,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
778,4,Headache,Headaches NEC,Headaches,Nerv,N
778,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
778,6,Neck pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
779,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
779,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
779,3,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
779,4,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
779,5,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
779,6,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
779,7,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
779,8,Rebound eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
779,9,Rebound effect,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
779,10,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
779,11,Skin fissures,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
779,12,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
780,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
780,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
780,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
781,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
781,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
781,3,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
781,4,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
781,5,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
781,6,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
781,7,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
781,8,Rebound eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
781,9,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
781,10,Skin fissures,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
781,11,Topical steroid withdrawal reaction,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
781,12,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
782,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
782,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
783,1,Central serous chorioretinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
784,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
785,1,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
786,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
786,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
787,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
788,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
789,1,Retinal disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
790,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
791,1,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
791,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
792,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
793,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
793,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
794,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
794,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
794,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
794,4,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
794,5,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
794,6,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
794,7,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
794,8,Rash pustular,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
794,9,Restlessness,Increased physical activity levels,Changes in physical activity,Psych,N
794,10,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
794,11,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
794,12,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
794,13,Skin weeping,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
794,14,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
795,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
795,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
795,3,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
796,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
797,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
797,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
798,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
798,2,Maternal exposure during breast feeding,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
798,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
798,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
799,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
800,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
800,2,Polymers allergy,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
800,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
800,4,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
801,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
801,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
801,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
801,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
801,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
802,1,Lip pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
802,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
803,1,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
803,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
804,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
804,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
805,1,Oral discomfort,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
805,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
805,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
806,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
806,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
806,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
806,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
806,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
806,6,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
807,1,Choking,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
808,1,Inflammation,Inflammations,General system disorders NEC,Genrl,N
809,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
809,2,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
809,3,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
809,4,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
810,1,Product administered at inappropriate site,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
810,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
810,3,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
811,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
812,1,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
812,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
812,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
813,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
813,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
814,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
814,2,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
815,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
815,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
815,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
816,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
817,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
817,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
818,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
819,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
820,1,Penile erythema,Penile disorders NEC (excl erection and ejaculation),Penile and scrotal disorders (excl infections and inflammations),Repro,N
821,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
822,1,Headache,Headaches NEC,Headaches,Nerv,N
822,2,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
822,3,Pain in jaw,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
822,4,Product administered at inappropriate site,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
822,5,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
822,6,Sinus congestion,Paranasal sinus disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
822,7,Skin induration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
822,8,Skin mass,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
822,9,Skin weeping,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
823,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
824,1,Scar,Skin injuries NEC,Injuries NEC,Inj&P,N
825,1,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
825,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
825,3,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
825,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
825,5,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
825,6,Skin weeping,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
826,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
826,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
827,1,Anal candidiasis,Candida infections,Fungal infectious disorders,Infec,N
828,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
828,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
828,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
828,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
829,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
829,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
830,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
